Science
Mechanism of Action
Bifonazole operates through a sophisticated dual-stage inhibition of fungal ergosterol biosynthesis, targeting both the lanosterol 14α-demethylase and HMG-CoA reductase enzymes. Beyond its antimicrobial reach, it suppresses keratinase activity and reduces pro-inflammatory mediators, offering symptomatic relief comparable to mild corticosteroids.
Research
Clinical Evidence
High confidence1%
Key findings
- 01 Clinical trials demonstrate 90-100% resolution of superficial mycoses within a 2-4 week application window.
- 02 Comparative data indicates anti-inflammatory performance at 1% concentration is equivalent to 1% hydrocortisone for reducing erythema and pruritus.
- 03 Preliminary evidence suggests efficacy in the management of seborrheic dermatitis and rosacea symptoms.
Transparency
Dusting Analysis
As a medicinal active, Bifonazole is rarely 'dusted' in cosmetic formulas; it is typically included at the full 1% therapeutic dose or omitted entirely due to its regulatory status as an OTC drug.
The Formula
Formulation
Stability
Highly lipophilic; while stable across a broad pH range (1-12) in various environments, physiological pH (5.5-7.0) is required for optimal skin barrier compatibility and stability.
Synergies
- Lipophilic delivery systems
- Emollients
Conflicts
- Strong oxidizing agents
- Latex materials
Safety
Safety Profile
Classified as a topical drug/OTC active rather than a standard cosmetic ingredient. Consult local regulations for formulation compliance.
Your Skin
Skin Compatibility
Our Assessment
Verdict
A high-performance therapeutic active for fungal-related skin concerns, though its use is restricted by its classification as a medicinal drug.
Related
Similar Ingredients
Finding similar ingredients…